U.S. Water Utilities Stock News

In recent weeks, National Energy Services Reunited Corp. reported strong Q4 and full-year 2025 results, with resilient margins supported by early activity at the Jafurah project and detailed in its latest 10-K filing. Analysts and research services have highlighted NESR’s improving earnings outlook and comparatively attractive valuation metrics, positioning it as a value-oriented oilfield services player in the MENA region with growing interest in sustainable solutions. Next, we’ll explore...

In late February and early March 2026, Rockwell Automation opened a new Bologna Customer Experience Center for EMEA manufacturers and announced that wheel maker Ronal Group is standardizing global remote access using Rockwell’s secure, NIS2-aligned technology. Together, these moves highlight how Rockwell is pairing hands-on digital transformation support with strengthened industrial cybersecurity to deepen its role in customers’ operations. We’ll now examine how the Bologna center’s focus on...

In the most recent quarter, Labcorp reported year-on-year revenue growth but came in slightly below analyst expectations, while raising its full-year earnings per share guidance following strong results in its Diagnostics and Central Laboratory units. This guidance increase, underpinned by businesses that touch more than 600 million tests annually and were involved with 90% of 2023 FDA-approved drugs, highlights how core operations are shaping management’s confidence in the earnings...

How Patria Investments (PAX) Has Been Trading Recently Patria Investments (PAX) has drawn attention after a weak recent trading stretch, with the share price declining about 10% over the past week, 17% over the past month, and 25% over the past 3 months. For investors, those moves sit alongside a 1 year total return of about 14%. This raises the question of whether current levels around US$11.81 fairly reflect the company’s earnings profile and business model in private markets asset...

In late February 2026, PROCEPT BioRobotics reported fourth quarter and full-year 2025 results showing higher sales but a larger net loss, and issued 2026 guidance calling for US$390 million to US$410 million in revenue, gross margin of about 65%, and a net loss of US$78,500,000 to US$91,500,000. Alongside this guidance, the company outlined 2027 targets, including 25% to 30% annual revenue growth and 68% to 70% gross margin, and soon after expanded its board to nine members by appointing...

Vistra (VST) is back in focus after strong customer interest in its 1.8-gigawatt nuclear facility and new power purchase agreements with Amazon and Meta, along with more upbeat analyst commentary. See our latest analysis for Vistra. At a share price of US$163.62, Vistra has seen a 9.34% 1 month share price return and a very large 5 year total shareholder return. This suggests momentum has been strong despite some shorter term dips as investors reassess earnings and clean energy contract...

Costco Wholesale (NasdaqGS:COST) has entered a partnership with Sesame and IVI RMA North America to expand affordable fertility care options for members. The collaboration offers coordinated access to fertility specialists, nationwide support, and discounts on related medications. The program is positioned as an extension of Costco's existing pharmacy and health offerings into more specialized care. For Costco, known primarily for its warehouse retail model and membership structure, this...

Henry Schein, Inc. recently reported fourth-quarter 2025 results showing sales of US$3,437 million and net income of US$101 million, alongside full-year 2025 sales of US$13.18 billion and net income of US$398 million, while also booking a US$15 million intangible asset impairment and completing a sizeable share repurchase program. At the same time, Henry Schein One introduced new Dentrix Ascend cloud packages built on an integrated, AI-enabled platform and the company issued 2026 sales...

In past months, several law firms announced securities class actions against Ultragenyx Pharmaceutical, alleging the company misled investors about the reliability and risks of Phase III Orbit and Cosmic trials for setrusumab in osteogenesis imperfecta, after the studies failed to reach statistical significance. The litigation raises questions about Ultragenyx’s clinical disclosure practices and could influence how investors view the company’s risk profile, capital allocation, and future...

In recent weeks, Krystal Biotech reported financial results for the fourth quarter of 2025 that exceeded analyst expectations for both earnings and revenue, while President and CEO Krishnan Krish S executed US$6.58 million of pre-planned stock sales under a Rule 10b5-1 trading plan. This combination of financial outperformance and insider selling offers fresh insight into how management is monetizing equity while the core business appears to be executing ahead of external forecasts. Next,...

MercadoLibre (MELI) recently drew fresh attention after its fourth quarter and full year 2025 earnings, reporting strong revenue and fintech traction but tighter margins as costs, loss reserves, and competition in Brazil picked up. See our latest analysis for MercadoLibre. Those earnings and margin concerns have quickly fed into the share price, with MercadoLibre now trading at US$1,769.52 after a 10.2% 1 month share price decline and a 9% 1 year total shareholder return. The 3 year total...

Recent commentary around Five Below (FIVE) focuses on its accelerating earnings, consistent EPS beats, solid sales growth, and cash flow strength, with the stock also showing constructive technical action that has caught investors’ attention. See our latest analysis for Five Below. Alongside its latest store opening in New Hampshire and recent technical strength flagged by market watchers, Five Below’s 1-month share price return of 8.5% and 90-day share price return of 25.4% sit against a...

Schneider National stock snapshot after recent performance Schneider National (SNDR) has seen mixed share performance recently, with a modest 1 day gain alongside declines over the past week and month, prompting investors to reassess its transportation and logistics profile. See our latest analysis for Schneider National. At a share price of $25.79, Schneider National’s recent 7 day and 30 day share price returns of 8.42% and 12.52% declines contrast with a 1 year total shareholder return of...

How Artisan Partners Asset Management stock has been performing Artisan Partners Asset Management (APAM) has attracted attention after a period of weaker share performance, with the stock showing a 0.9% decline over the past day and a 17.9% decline over the past month. Over the past 3 months, Artisan Partners Asset Management has recorded an 11.1% decline, while the year to date return stands at a 10.6% decline and the 1 year total return at a 4.5% decline. Looking further back, the 3 year...

Immunocore Holdings plc recently reported fourth-quarter 2025 revenue of US$104.48 million and a quarterly net loss of US$30.06 million, alongside full-year 2025 revenue of US$400.02 million and a full-year net loss of US$35.51 million. The company paired this earnings update with a packed schedule of March 2026 healthcare conference appearances in Boston and Miami, signaling active engagement with investors and the broader biotech community. We’ll now examine how the full-year revenue...

Papa John's International, Inc. recently reported weaker fourth-quarter and full-year 2025 results, with revenue slipping to US$498.18 million in Q4 and full-year net income falling to US$30.53 million, and guided for global system-wide restaurant sales in 2026 to be flat to down low single-digits. The company also plans to close about 200 North American stores and pursue cost optimization programs targeting at least US$25 million in savings by 2027 and US$60 million in supply chain savings...

RBC Bearings Incorporated recently presented at the 47th Annual Raymond James Institutional Investor Conference in Orlando and released a mixed quarter, with year-on-year revenue growth supported by its Aerospace & Defense operations and steady Industrial performance. Management highlighted a growing aerospace and defense backlog, a focus on profitable growth, and expanding production capacity, underlining efforts to strengthen long-term cash generation and contract visibility. Next, we’ll...

Alpine Income Property Trust, Inc. recently originated a US$32.0 million first mortgage loan, funding US$8.6 million at close, to back the development of an 11‑acre, 101,000‑square‑foot retail center with investment grade tenants and three outparcels in the Covington Town Center master plan near Atlanta. The high‑coupon, 24‑month loan tied to a Target‑anchored project adjacent to an existing Publix highlights Alpine’s growing use of higher‑yield structured financing alongside its net lease...

Westlake Corporation has reported its fourth-quarter 2025 results, with sales of US$2,533 million and a net loss of US$544 million, compared with a small profit a year earlier. For 2025 as a whole, Westlake’s sales declined to US$11.17 billion and the company moved from a net income of US$602 million to a net loss of US$1.51 billion, sharply reversing its prior profitability. We’ll now examine how this swing from profit to a sizeable loss may affect Westlake’s earlier investment narrative...

Phase 2 NDV-01 data and what it could mean for Relmada Therapeutics (RLMD) Relmada Therapeutics (RLMD) has drawn fresh attention after reporting 12 month interim Phase 2 data for NDV-01 in high risk non muscle invasive bladder cancer, showing strong complete response rates and a favorable safety profile. See our latest analysis for Relmada Therapeutics. The NDV-01 update and recent Leerink healthcare conference appearance came alongside a sharp shift in sentiment, with Relmada Therapeutics’ 1...

Bausch + Lomb (BLCO) is drawing fresh attention after announcing an upcoming R&D webinar focused on its glaucoma pipeline, including drug candidate BL1107 and the ELIOS minimally invasive glaucoma surgery platform. See our latest analysis for Bausch + Lomb. The upcoming glaucoma webinar follows a mixed stretch for the stock, with a 1-day share price return of 0.94% and a 7-day share price decline of 6.46%. This sits alongside a 1-year total shareholder return of 8.30% and a 3-year total...

Ichor Holdings recently presented at the Stifel 2026 NYC Technology One-on-One Conference at The Conrad New York Downtown, offering investors detailed updates on its semiconductor equipment business. A sharp sector-wide reset in semiconductor sentiment, driven by fresh regulatory and geopolitical concerns, has put additional focus on how resilient Ichor’s fundamentals and long-term positioning really are. We’ll now examine how this sector-wide regulatory uncertainty, rather than...

Earnings, guidance and new buyback set the backdrop DoubleVerify Holdings (DV) is in focus after reporting full year 2025 results, issuing 2026 revenue guidance and unveiling a new US$300 million share repurchase program on February 26. Sales for 2025 came in at US$748.29 million versus US$656.85 million a year earlier, while net income was US$50.65 million compared with US$56.23 million. Basic earnings per share from continuing operations were US$0.31, with diluted earnings per share at...

Axsome Therapeutics recently dosed the first patient in its CLARITY Phase 3 trial of solriamfetol for major depressive disorder with excessive daytime sleepiness and has also been granted FDA Priority Review for AXS-05 in Alzheimer’s disease agitation, while management engaged investors at several March healthcare conferences. Together, the new late-stage solriamfetol study and the upcoming AXS-05 regulatory decision highlight how Axsome is steadily broadening its central nervous system...